Analytical Data
-
Gene name
PSENEN
- Application
-
Alternative Names
PSENEN；PEN2；Gamma-secretase subunit PEN-2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NZ42
-
Expression Region
1-101aa
-
AA Sequence
MNLERVSNEEKLNLCRKYYLGGFAFLPFLWLVNIFWFFREAFLVPAYTEQSQIKGYVWRSAVGFLFWVIVLTSWITIFQIYRPRWGALGDYLSFTIPLGTP
-
Molecular Weight
12.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PSENEN (Presenilin Enhancer 2) is a crucial protein involved in the processing of amyloid precursor protein (APP), which is significant in the pathogenesis of Alzheimer’s disease. As a part of the gamma-secretase complex, PSENEN is responsible for the cleavage of APP, leading to the production of amyloid-beta peptides that aggregate into plaques, a hallmark of Alzheimer’s pathology. Mutations in PSENEN, alongside other components of the gamma-secretase complex, have been linked to familial forms of Alzheimer's disease, highlighting its essential role in neuronal integrity and function. Research on PSENEN has gained momentum due to its potential as a therapeutic target; understanding its structure and functional mechanisms could pave the way for innovative strategies in Alzheimer's treatment. Moreover, recombinant PSENEN protein is instrumental for in vitro studies, allowing researchers to dissect the biochemical pathways involved in gamma-secretase activity and identify new modulators that could influence the aberrant processing of APP. By elucidating the role of PSENEN in amyloidogenesis, researchers aim to contribute to the broader understanding of Alzheimer’s disease and explore the development of novel interventions that may slow down or halt the progression of this debilitating condition. Studies utilizing recombinant PSENEN also facilitate the investigation of protein-protein interactions and the exploration of PSENEN's influence in other cellular processes, further emphasizing its importance in neurobiology and potential as a biomarker for disease progression. The ongoing research endeavors aim to provide insights that are critical for the advancement of therapeutic approaches targeting the underlying mechanisms of Alzheimer’s disease.
